During tumor progression, cancer cells rewire their metabolism to face their bioenergetic demands. In recent years, microRNAs (miRNAs) have emerged as regulatory elements that inhibit the translation and stability of crucial mRNAs, some of them causing direct metabolic alterations in cancer. In this study, we investigated the relationship between miRNAs and their targets mRNAs that control metabolism, and how this fine-tuned regulation is diversified depending on the tumor stage. To do so, we implemented a paired analysis of RNA-seq and small RNA-seq in a breast cancer cell line (MCF7). The cell line was cultured in multicellular tumor spheroid (MCTS) and monoculture conditions. For MCTS, we selected two-time points during their development to recapitulate a proliferative and quiescent stage and contrast their miRNA and mRNA expression patterns associated with metabolism. As a result, we identified a set of new direct putative regulatory interactions between miRNAs and metabolic mRNAs representative for proliferative and quiescent stages. Notably, our study allows us to suggest that miR-3143 regulates the carbon metabolism by targeting hexokinase-2. Also, we found that the overexpression of several miRNAs could directly overturn the expression of mRNAs that control glycerophospholipid and N-Glycan metabolism. While this set of miRNAs downregulates their expression in the quiescent stage, the same set is upregulated in proliferative stages. This last finding suggests an additional metabolic switch of the above mentioned metabolic pathways between the quiescent and proliferative stages. Our results contribute to a better understanding of how miRNAs modulate the metabolic landscape in breast cancer MCTS, which eventually will help to design new strategies to mitigate cancer phenotype.

Keywords: cancer metabolism, miRNA-mRNA interaction, multicellular tumor spheroids, bioinformatics, miRNA target prediction
INTRODUCTION

MicroRNAs (miRNAs) are small non-coding RNAs of approximately 22 nucleotides in size that are related to critical regulatory functions in a plethora of biological processes, associated with healthy and dysfunctional physiological states (1, 2). The most common and well-documented functions of miRNAs are to be endogenous negative regulators of the translation and contribute to the miRNAs instability. This regulatory capacity is carried out through direct base pairing to the target sites in the 3′ untranslated regions of an mRNA (3). To date, there are more than 1,900 mature human miRNAs according to the latest build (build 22) of the Sanger Centre miRNA database miRBase (http://www.mirbase.org). To highlight their regulatory relevance, last estimations suggest that this set of miRNAs target at least 60% of human mRNAs (4). For this reason, miRNAs have surged as crucial post-transcriptional regulators whose dysregulation can be tightly associated with aberrant gene expression in complex human diseases such as cancer (5).

In cancer research, there are a myriad of publications uncovering the role of miRNAs during their pathogenesis and progression (6, 7). Despite their broad dysregulation, miRNAs can be functionally classified as oncogenes or tumor suppressors (8). This fact leads to most of the human tumors present a unique pattern of expression, setting a large and complex network of interactions between oncogenes being activated and the loss of various tumor suppressors. Regardless of this variation in the genetic profiles, these interactions between oncogenes and tumor suppressors can directly or indirectly induce metabolic alterations that favor the survival and growth of the tumoral cells (9). For instance, there is experimental evidence that miRNA-143 down-regulates Hexokinase 2 (HK2) which promotes cancer progression and the reduction in glucose metabolism (10). Hence, miRNAs participate in the control of metabolic reprogramming by regulating the expression of mRNAs whose protein products regulate directly metabolic machinery (11, 12). Despite the substantial progress in this area, we still need to complete the puzzle and establish the role of miRNAs on metabolic rewiring into cancer progression and how this could be exploited as therapeutic targets in cancer.

A major impediment in cancer treatment is the drug resistance due to the heterogeneous subpopulations of cells within the tumor with different cell-cycle phases (13, 14). The cell cycle is the mechanism associated with proliferation, cellular division and DNA replication. It is mainly divided into four phases: G1-phase where proteins necessary for S-phase progression are accumulated, the S-phase period where DNA synthesis occurs, the G2-phase where proteins required for mitosis are produced and the M-phase where mitosis and separation occurs (15). Also, cells may occasionally exit from the cell-cycle and enter a phase of quiescence called the G0-phase (16). With this in mind, models that closely resemble human cancer cell-cycle heterogeneity are essential for understanding the growth mechanisms and for the development of new treatments. For this reason, MultiCellular Tumor Spheroids (MCTS) models have been used to study and reproduce the gradients between proliferating and quiescent cells, cell-cell interaction, low drug penetration and resistance of quiescent cells located in the deepest and hypoxic regions (17–19).

In the present study, we proceeded with a experimental and computational pipeline to report new plausible miRNA-mRNA pairs interactions involved in the metabolic rewiring of cancer, using an in vitro MCTS model of a luminal A breast cancer cell line (MCF7), the most prevalent subtype in women worldwide (20). To explore the regulatory effect of miRNAs over metabolism, we accomplished a longitudinal study of the MCTS in a period of 19 days of progression. In this interval of time, the MCTS owns cell populations with different cell cycle stages, particularly proliferative and quiescent cells, which can provide differences in the metabolic phenotype as time passes. Using this model, we conducted a whole transcriptome analysis, including RNAs and small-RNAs, to describe how miRNAs influence metabolism. Our paired analysis of RNAseq and small RNAseq allowed us to conclude that whereas glycerophospholipid and glucose metabolism are down-regulated in proliferative enriched MCTS, oxidative phosphorylation, and amino acid biosynthesis is down-regulated in quiescent enriched MCTS. Overall our study highlighted the crucial role of miRNAs to guide the metabolic phenotype in MCF7 MCTS. Notably, the set of miRNAs modulating the expression of various metabolic mRNAs seems to be a promising avenue to design new in vitro strategies to mitigate the malignant phenotype in cancer.

MATERIALS AND METHODS

Experimental Procedures

MCF7 Monoculture

Breast cancer cell line MCF7 (ATCC HTB-22TM, Manassa, VA, USA) was grown in DMEM (ATCC 30-2002, Manassa, VA, USA) containing 4 mM L-glutamine, 4,500 mg/L glucose, 1 mM sodium pyruvate, and 1,500 mg/L sodium. Media was supplemented with 10% v/v of FBS (ATCC 30-2020, Manassa, VA, USA). The media was replaced every 2 days with fresh media. Cells were incubated under a humidified atmosphere with 5% CO2 and 95% air at 37°C. For all experiments, 70—80% confluent monoculture with less than 9 passages were used. MCF7 cell line was validated using STR analysis.

Generation and Disaggregation of Multicellular Tumor Spheroids (MCTS) Cultures from MCF7

The generation of MCTS was carried out using a liquid overlay technique. A single-cell suspension of MCF7 at a density of 1x10⁶ cells was loaded into 12.5 cm² suspension culture flasks (UltraCruz sc-200257, Tex, USA) containing 5 mL of L-15 media (ATCC 30-2008, Manassa, VA, USA) supplemented with 5% v/v of FBS. Flasks were placed in an orbital incubator at 37°C under constant orbital shaking of 59 rpm for 6 and 19 days (21). The media was replaced every 2 days with fresh media.

For disaggregation, the 6 and 19 day-old MCTS were heated and transferred to 1.5 mL tubes. The MCTS were washed with PBS 1X (VWR 97062-732, PA, USA). Accutase (Invitrogen 00-4555-56, CA, USA) was added and the reaction was carried out for 45 min. at 37°C with orbital shaking. Every 5 min. the MCTS were mixed gently by pipetting during the accutase reaction. To ensure optimal disaggregation, Trypsin-EDTA (0.25% Trypsin, 1mM EDTA) solution was added for 5 min at 37°C. The trypsin reaction was stopped by adding media with FBS in a 1:1 ratio. Finally, cells were
collected by centrifugation and were suspended in 0.1% BSA in PBS (Cell Signaling Technology BSA #9998, USA) solution.

**MCTS Diameter Distribution**

Diameter distribution of MCTS at 4, 7, 11, 15, 17, and 19 day-old time was estimated by two steps. First, we took photos directly to the MCTS culture, ensuring that almost all MCTS are positioned at the center of the flask. Photos were taken using a Nikon Eclipse TS100 Inverted Microscope. Following this, the images were analyzed through the MorphLibJ package to directly estimate the Feret diameter of all the MCTS in each picture (22). The Feret diameter value reported in Figure 1 represents the mean value of all MCTS properly measured for each time point. The diameter distribution was calculated for three independent MCTS cultures using the time points mentioned above (Table S1).

**MCTS Culture Time Points Selection**

To evaluate the abundance of cells in proliferative and quiescent stages inside the MCTS through time, we selected four-time points: 6, 8, 17, and 19 days. The first two time points (6 and 8 days) of MCTS culture were chosen because after 6 days almost every cell has been aggregated to form an MCTS. The next two time points were picked because after 20 days of MCTS culture necrotic population started to appear, a condition that was avoided in our study.

**Immunophenotyping**

The 6-, 8-, 17-, and 19-day old MCTS cultures were disaggregated as described in *Generation and Disaggregation of Multicellular Tumor Spheroids (MCTS) Cultures from MCF7* section. Therefore, we took an aliquot of 3x10^6 cells of each MCTS culture. Fixation was carried out using PFA 4% for 10 min. at room temperature and rinsing three times with PBS 1X. Subsequently, the permeabilization was accomplished by adding ice-cold methanol (90%) during 30 min. in ice. Previous to the antibody staining, the methanol was removed by washing with PBS 1X and 1x10^6 cells were aliquoted. Then, the cells were rinsed with 3 mL of incubation buffer (0.1% BSA in PBS) three times. Staining was made by resuspending the cells with the Ki67-Alexa Fluor® 488 Conjugate (CST 11882, Massachusetts, USA) and p27-PE Conjugate (CST 12184, Massachusetts, USA) primary antibodies (1:50) and incubating for 1 h at room temperature. Before cell cytometry analysis, cells were resuspended in 500 µL of PBS 1X. Finally, the immunophenotyping was done in a FACSARia Cell Sorter.

**RNA Extraction Method for MCTS and Monoculture**

Total RNA was isolated from MCF7 monoculture, 6- and 19-day old MCTS by a TRIzol (Invitrogen, CA, USA) adapted protocol. Particular adjustments previous to the TRIzol extraction were made for both culture conditions. In the monoculture, we used a 70–80% confluent culture, then we poured 1 mL of TRIzol directly to the culture dish and homogenized until all cells were detached from the dish. This step was assisted by the use of a scraper. In the 6- and 19-day old MCTS culture, the MCTS were retrieved by centrifugation and resuspended in 1 mL of TRIzol. The solution was homogenized vigorously until there were no cellular lumps. The subsequent steps described below were used for both culture conditions. We added 10 µL of triton 2% (Merck T8787, St. Louis, USA) and incubated for 10 min. at room temperature. Next, we added 200 µL of chloroform, mixed through inversion and incubated for 5 min. at room temperature. Tubes were centrifuged at 12,000 rpm during 15 min. at 18°C. The aqueous phase was retrieved, we added 0.25 µL of glycogen as co-precipitation reagent (ThermoFisher R0561, Waltham, USA) and isopropanol was added in a 1:1 ratio (regarding TRIzol). The mixture was homogenized gently, incubated for 20 min. at −20°C and centrifuged at 13,000 rpm during 45 min. at 18°C. Finally, the pellet was washed three times with ethanol 75%, dissolved in ultrapure DDW (not treated with DEPC) and stored at −80°C.

**FIGURE 1** | MCF7 MCTS Model. (A) Representative images from MCF7 MCTS culture showing size differences along time. (B) MCTS diameter distribution measurements, average MCTS measure per time point = 67, n = 3. (C) Immunophenotyping of MCTS subpopulations with flow cytometry using Ki67 and p27 markers in four temporal conditions: day 6, 8, 17, and 19. The expression of both markers showed statistical difference in the comparison between days 6 and 19. Single asterisk indicates a statistical difference, P <0.05 (unpaired t-test with equality of variances in normalized measurements, t = ± 4.4629; df = 4).
RNA-Seq and Small RNA-Seq Library Construction and Sequencing

Previous to the library construction we ensured that all RNA samples have a minimum amount of 1 µg and the integrity value of the samples have a RIN >7. The NGS was performed on total RNA isolated as described in the previous section using the NextSeq platform (Illumina, Inc.). The library construction for RNA-Seq and small RNA-Seq was made following the TruSeq RNA Library Prep Kit (Illumina, Inc.) and the CD Small RNA Library Prep Kit (Illumina, Inc.), respectively. The datasets presented in this study can be found in online repositories. The names of the repository and accession number can be found below: ArrayExpress, Accession: E-MTAB-9741 (https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-9741/)

Bioinformatic Analysis

Quality Determination and Pre-Processing

All the FASTQ files undergo quality evaluation using FastQC software version 3 (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). The resulting output files were summarized using the MultiQC tool (23). Only RNA-Seq FASTQ files were pre-processed to remove low-quality information in the 3’ and 5’ end using Trimmomatic version 0.36 (24).

Alignment and Entity Quantification

For RNA-Seq FASTQ pre-processed files, the alignment was made using Kallisto version 0.43.1 (25). The results were summarized using the tximport package in R (26). For small RNA-Seq the alignment was made using Bowtie2 version 2.3.2 (27) with the parameters suggested in (28) and the human genome GRCh38 construction. The resulting SAM files were summarized using FeatureCounts (29) with the hsa.gff file from miRBase v22.

Exploratory Analysis and Differential Expression Analysis

The processed data was inspected for normalized data through principal component analysis (PCA) plot (Figure S1). The differential expression analysis was carried out with edgeR package (30) version 3.26.8 for RNA-Seq and small RNA-Seq reads.

miRNAs Target Prediction for Metabolic mRNAs

To only obtain the Differential Expressed (DE) metabolic mRNAs in each condition, we filtered the DE mRNAs using the KEGG metabolic pathways gene list using an FDR <0.05 threshold. Next, we used DE miRNAs and the metabolic DE mRNAs mentioned before to obtain the plausible miRNAs-mRNA pairs calculated with miRGate (31). From miRGate analyses we only used the predictions from Targetscan algorithm and the experimental validated miRNA-mRNA pairs for further filters. We filtered the plausible pairs when the log2FC has an inverse value between miRNAs and the metabolic mRNAs. Finally, the selected pairs were filtered to those who appear at least two times in a metabolic pathway.

Pathway Enrichment Analysis

Pathway enrichment analysis was done using two different methods within Webgestalt (32). First method consists of taking the full mRNA list into an over-representation analysis (ORA). Second, gene set enrichment analysis (GSEA) was made using the mRNA differential expressed with a FDR <0.05. We used the KEGG, GO, Panther, and wikipathway datasets.

RESULTS

MCTS Culture as a Model of Proliferation and Quiescence

To explore the possible interaction between miRNAs and mRNAs of metabolic genes in cancer, we carried out a MCTS culture with the breast cancer cell line MCF7. We mainly used the human luminal A (ER+, PR+, HER2-) cell line due to its high incidence in women breast cancer patients worldwide (20). In this MCTS model, MCF7 cell suspension was loaded on non-adherent plates to stimulate cell-cell adhesion and promote well-rounded spherical structures. This experimental model, and its implemented protocols, facilitated the tracking of the progression of the MCTS and ensured the production of large batches of MCTS on diverse time points (Figure 1A). The Feret Diameter reported in Figure 1B, is the average value of MCTS measurements in each time point (Table S1). To select the optimal time point where the MCTS is mainly enriched in a cell cycle phase, we assess the presence of a standard marker for proliferation (Ki67) and quiescence (p27) in four-time points using immunophenotyping. Also, to contrast the differences across a classical culture method, we included a 2D model (monoculture) along all the study to compare against a proliferative enriched MCTS and quiescent enriched MCTS. We applied a t-test analysis over the relative composition of the proliferative and quiescent population in monoculture and MCTS to identify two sample times to proceed with NGS data analysis. The statistical analysis showed significant differences in some samples between the expression of Ki67 and p27 (Figure S2). As a result of this study, we found that only the comparison between MCTS at 6- and 19-day old showed statistical differences in both cell cycle markers (Figure 1C). Consequently, these time points were selected to carry on the transcriptome and small-RNA profiling. These results indicate that MCTS 6-day old are primarily enriched in proliferative cells (P-MCTS), and MCTS 19-day old are principally enriched in quiescent cells (Q-MCTS).

Bioinformatics Analysis of RNA-Seq and Small RNA-Seq

To date, few computational tools can simultaneously accomplish the analysis of RNA-Seq and small RNA-Seq. Among these algorithms, miARma-Seq provides a multiprocess analysis tool that can undergo these restraints and allow the study of expression profiles of miRNAs and their targeted mRNAs (33). A study combining mRNA and miRNA sequencing can undoubtedly supply a proper framework to assess pair-wise connections between miRNAs and metabolic targets mRNAs. With this aim in mind, we implemented some changes in the original miARma-Seq pipeline, using the best-suited tools for each processing module. The two significant changes in the pipeline were performed in the alignment tool for RNA-Seq data and the enrichment tool. Thus, we set Kallisto and Webgestalt as the new processing tools (Figure 2). An in-depth description of the adjustments made for each processing module is described in the methods section. In brief, our pipeline is
integrated by a set of modules which embraces classical steps for each technology (mRNA and microRNA) such as quality check, alignment, differential expression, target prediction, and functional analysis. A global view of the entire pipeline implemented in this paper is depicted in Figure 2.

Differential Expression Analysis and Metabolic mRNAs Target Prediction
In this section, we pursue two aims: explore how miRNA and mRNAs expression changes among conditions; and identify potential miRNAs-mRNA regulatory mechanisms at a metabolic level. To assess the changes in RNA expression profiles among the samples, we obtained the Differential Expressed (DE) profile of mRNAs and miRNAs for each pair-wise comparison among P-MCTS, Q-MCTS, and monoculture condition. From a statistical point of view, we used an FDR <0.05 as a criteria to select those mRNAs and miRNAs differentially expressed between conditions. As a result, we identified a total of 1,289 mRNAs and 35 miRNAs differentially expressed among all pairwise conditions. Particularly, the comparison between P-MCTS and monoculture showed no significant results. Therefore, to get insight of the regulation differences we used only for this comparison a p-value <0.05. By doing so, 15 unique miRNAs were added to the analysis. Figure 3A summarize the set of DE mRNAs and miRNAs obtained per comparison with the considerations indicated above.

In order to disentangle the metabolic rewiring accomplished by miRNAs, we carried out a filter within the DE mRNAs to just obtain the subset of mRNAs that codify for metabolic machinery. This last analysis was accomplished by using the KEGG metabolic pathways gene set (3-4). Subsequently, miRGate was used to characterize in silico potential regulatory interactions between the DE metabolic mRNAs and the miRNAs. As a result of this bioinformatic analysis, 32 mRNAs and 24 miRNAs were selected as miRNA-RNAs interactions obtained with the considerations described in the miRNAs target prediction for metabolic mRNAs section. To dissect which of these miRNAs-mRNAs regulatory interactions between miRNAs and metabolic mRNAs are unique or shared across the cultured conditions, we visually recap their comparison in Figure 3B. As shown in this last figure, the numerical distribution and percentage of miRNA and their predicted DE mRNA targets shared and specific for each condition are shown in Figure 3B. In the next section, we present an in-depth analysis over these pairs of miRNAs-mRNA interactions and its possible functional consequences.

Metabolic mRNAs-miRNAs Pairs Functions
In the previous section, we identified a set of 24 miRNAs and 32 mRNAs that could have a regulatory effect in the metabolic pathways for the three comparisons. Based on this set of 24 miRNAs and 32 mRNAs, in this section we explored their pattern of expression and their possible influence on signaling and metabolic pathways for each pairwise condition, see Tables 1–3. In general terms, miRNA-mRNA pairs could influence different signaling and metabolic pathways, obtained as described in miRNAs Target Prediction for Metabolic mRNAs section. For instance, in the comparison between Q-MCTS and P-MCTS, we observed an upregulation of mRNAs in fatty acids and lipid metabolism. Also, we noted a downregulation of the biosynthesis of amino acids. Furthermore, mRNAs participating in glycolysis, oxidative phosphorylation, and glycan metabolism do not show a particular preference for a comparison due to the disparity in the pathway usage (Table 1). Comparative analysis between Q-MCTS and monoculture showed an up-regulation in mRNAs participating in lipid metabolism, particularly the glycerophospholipid metabolism. Notably, although we had a different set of DE mRNAs in each condition, we observed that mRNAs in glycerophospholipid metabolism remain up-regulated in Q-MCTS with respect to all comparisons.

Among the exclusive overexpressed pathways in monoculture, we stand out the inositol phosphate metabolism, purine metabolism, glycosaminoglycan metabolism, and pathways such as calcium and sphingolipid signaling pathways. The carbon metabolism for this comparison also showed differences in pathway usage (Table 2). Finally, the comparison between P-MCTS and monoculture showed a preference for the biosynthesis and degradation of the amino acids, the inositol metabolism, and glycerophospholipid metabolism in P-MCTS. The monoculture condition does not show a particular pathway usage for this comparison; however there is an overexpression in GFPT2, suggesting a UDP sugar metabolism preference (Table 3).

Functional Analysis
To obtain a global perspective in the pathways usage in the whole mRNA data, we accomplished a gene set enrichment analysis over all the samples together. To this end, we applied an Over Representation Analysis (ORA) and selected those pathways with an FDR ≤0.05. This primary study allowed us to identify pathways that change over all the samples. Interestingly the enrichment suggested pathways involved in the spliceosome, cell cycle, proteolysis, protein processing, RNA transport, carcinogenesis, thermogenesis, endocytosis, and metabolic pathways (Figure 4A). The results recapitulate pathways according to the selection of the samples, such as the cell cycle. However, this method did not allow us to distinguish in which condition the pathway was over-represented. Thus, we use a complementary approach to achieve a more specific insight into the pathways usage between comparisons. We carried out a GSEA using different datasets for all pairwise comparisons. Figures 4B–D depicts some of the main enrichment pathways defined in the KEGG database. In general terms, we noted that most overrepresented pathways lead to abnormal immune responses, metabolic rewiring, cell division, subversion of cellular signaling pathways, and DNA replication and repair. When comparing Q-MCTS vs. P-MCTS, we observed an up-regulation of mRNAs in inflammatory responses and immune suppression and a downregulation of steroid biosynthesis, cell division, and DNA replication and repair (Figure 4B).

Comparative analysis between Q-MCTS and monoculture showed an up-regulation in mRNAs participating in steroid biosynthesis, glycerolipid metabolism and pathways involved in abnormal immune responses, and a downregulation of ascorbate, aldolase and drug metabolism, cell division, and DNA replication and repair (Figure 4C). Taking these results together, we noticed that the enriched pathways for the proliferative-like culture methods (P-MCTS and monoculture) are very similar when compared to Q-MCTS. Besides, Q-MCTS maintains the enrichment in pathways involved in abnormal immune responses. Finally, the comparison
between P-MCTS and monoculture showed an up-regulation in mRNAs participating in arginine and proline metabolism and a downregulation in the immune responses and the cellular signaling pathways (Figure 4D).

**DISCUSSION**

This study investigated the possible regulatory interactions between miRNAs and its metabolic mRNAs targets in the human breast cancer cell line MCF7. This aim was particularly carried out by applying and analyzing simultaneously RNA-seq and small RNA-Seq of MCTS and monoculture. As a result, two main findings can be highlighted. First, we provide new insights into the regulatory mechanism by which miRNAs modulate metabolic mRNAs to sustain cancer MCTS. Second, we have accomplished an in-depth bioinformatics analysis to characterize these miRNA regulations, and evaluate their consequences over pathways sustaining phenotype in Q-MCTS, P-MCTS, and
monoculture conditions. In the following, we discuss and draw some conclusions for each pairwise culture comparison.

**Q-MCTS vs. P-MCTS Comparison**

The comparison between Q-MCTS and P-MCTS reveals that Q-MCTS primarily have low expression in miRNAs that control the lipid metabolism and hexokinase 2 (HK2), setting a high preference for glycerophospholipid and glycolytic metabolism usage. On the other hand, P-MCTS down-regulates some miRNAs that control the biosynthesis of amino acids and oxidative phosphorylation through the targeting of NDUFb6 mRNA (Table 1). These results agreed with previous observations dealing with miRNAs and cancer cell metabolism. For instance, HK2 is the first rate-limiting enzyme of glycolysis, and its activity has been predicted to be regulated by multiple miRNAs including the confirmed negative regulation by miR-143 in breast cancer cell lines (12). Here, we suggested a new regulatory interaction in HK2 mRNA mainly carried out by miR-3143 and preferentially activated in P-MCTS when compared with Q-MCTS (Figure 5A).

In addition to the carbon metabolism, differences in the amino acid and lipid metabolism have been reported before and consistently observed in this study, see Figure 5A. Lipids are essential biosynthesis molecules for organelles and cells. The disturbance in lipid metabolism guided by miRNA regulation is a particular feature of cancer metabolism (35–37). Here, we propose that miR-7974 and miR-181a-5p regulate a set of mRNAs implicated in the lipid metabolism, predominantly the glycerophospholipid metabolism. These miRNAs are downregulated in Q-MCTS suggesting that the lipid metabolism remains active. Meanwhile the lipid metabolism is downregulated in P-MCTS by the list of miRNAs mentioned in Table 1. Moreover, cancer cells have an increased demand for amino acids to meet their rapid biosynthesis of proteins, nucleotides and lipids, redox homeostasis, and energy metabolism. There is evidence that miRNAs regulate amino acid catabolism in kidney cancer (38). In our study, we observed that the low expression of miRNAs regulating GLUL and PGAM1 mRNAs in P-MCTS assists their rapid proliferation, maintaining a high expression in these mRNAs to conserve the serine and glutamine pools. In Q-MCTS, the overexpression of miR-663a and miR-1184 can downregulate the amino acid metabolism to mainly depend only on a glycolytic and lipid metabolism (Figure 5A).

Regarding the oxidative phosphorylation findings, the overexpression of ATP6V1C1 in Q-MCTS, while in P-MCTS this mRNA is downregulated by miR-15a-5p. The ATP6V1C1 gene encodes a component of vacuolar ATPase (V-ATPase). The V-ATPase complex is located at the plasma membrane and plays an important role in tumor growth and metastasis by the increment in H+ secretion, granting tumor cells to survive in hypoxic conditions.
conditions and the consequent acidic tumor microenvironment (39). Also, in a mouse breast cancer model was shown that the Atp6v1c1 knockdown reduced invasion and migration (40). Based on these facts, we suggest that the rewiring of the metabolic program in Q-MCTS is due to the hypoxic conditions within the MCTS that aid in acquiring a metastatic phenotype in the quiescent subpopulation, unlike of its proliferative counterpart (Figure 5A).

Finally, we found that the dependence in the N-Glycan metabolism is guided by two miRNAs: STT3B and MGAT5. The expression of these miRNAs show an inverse regulatory phenotype. While STT3B mRNA is mainly down-regulated in P-MCTS by a group of miRNAs (miR-3143, miR-671-5p, and miR-454-3p), MGAT5 mRNA is down-regulated in Q-MCTS by miR-1184. The branching of the N-Glycans is implicated in the regulation of cell survival and proliferation (43). In concordance with our findings, the pathway usage correlates with the high proliferative rate seen by immunophenotyping with Ki67 (Figure S2).

**Q-MCTS vs Monoculture Comparison**

The comparison between Q-MCTS and monoculture reveal that Q-MCTS primarily has low expression in some miRNAs that control the glycerophospholipid biosynthesis and the glycolytic metabolism, suggesting a high preference for these metabolic pathways. On the other hand, monoculture down-regulates miRNAs regulating purine metabolism, inositol metabolism, sphingolipid metabolism, and glycosaminoglycan biosynthesis (Table 2). The obtained results showed that the down-regulation in the glycolytic metabolism, mainly in HK2 is in agreement with previous cancer metabolism reports. Here, we suggested a new regulation carried out by miR-362-5p on HK2, which is intensified in monoculture and diminished in Q-MCTS (Figure 5B).

Intriguingly, the down-regulation of HK2, is a frequent feature of the proliferative-like models (P-MCTS and Monoculture), although it is guided by different miRNAs depending on the culture method. These results supply additional evidence pointing out that the Q-MCTS depends on a glycolytic metabolism.

Additionally, the results showed an overexpression of miRNAs of the purine metabolism in the monoculture. We also suggested that this pathway is controlled by miR-3648, miR-663b, and miR193a-5p targeting ADA, AMPD2, and HPRT1, respectively in Q-MCTS (Figure 5B). The purines are essential components for RNA and DNA production and provide the cofactors and energy to support cell survival and proliferation (43). In concordance with our findings, the pathway usage correlates with the high proliferative rate seen by immunophenotyping with Ki67 (Figure S2), suggesting its essential role in monoculture.

On the other hand, fructose and mannose metabolism seems to have significant changes between these conditions. Based on our analysis, we concluded that these pathways can be altered by two
### TABLE 2 | Pathways affected by the mRNA-miRNA pairs for the comparison between Q-MCTS and monoculture.

| mRNA-miRNA Pairs | Pathway                                      | Expression |
|------------------|----------------------------------------------|------------|
| hsa-miR-7974     | Phosphatidylinositol signaling system        | +/−        |
|                  | DGKG                                         | +/−        |
|                  | INPP5A                                       | −/+        |
|                  | INPP5A                                       | −/+        |
|                  | DGKG                                         | +/−        |
|                  | PLA2G3                                       | −/+        |
|                  | PLD3                                         | −/+        |
|                  | INPP5A                                       | −/+        |
|                  | INPP5A                                       | −/+        |
|                  | MGDPP                                        | −/+        |
|                  | ADA                                          | −/+        |
|                  | HK2                                          | −/+        |
|                  | KHK                                          | −/+        |
|                  | GMPPB                                        | −/+        |
|                  | XYL2                                         | −/+        |
|                  | NDST1                                        | −/+        |
|                  | DGKG                                         | +/−        |
|                  | PLA2G3                                       | +/−        |
|                  | INPP5A                                       | −/+        |
|                  | INPP5A                                       | −/+        |
|                  | DGKG                                         | +/−        |
|                  | PLA2G3                                       | +/−        |
|                  | INPP5A                                       | −/+        |
|                  | INPP5A                                       | −/+        |
|                  | HK2                                          | −/+        |
|                  | HK2                                          | −/+        |
|                  | GDG                                          | −/+        |
|                  | GMPPB                                        | −/+        |
|                  | HK2                                          | −/+        |
|                  | HK2                                          | −/+        |
|                  | DGKG                                         | +/−        |
|                  | PLA2G3                                       | +/−        |
|                  | INPP5A                                       | −/+        |
|                  | INPP5A                                       | −/+        |
|                  | DGKG                                         | +/−        |
|                  | PLA2G3                                       | +/−        |
|                  | INPP5A                                       | −/+        |
|                  | INPP5A                                       | −/+        |
|                  | INPP5A                                       | −/+        |
|                  | DGKG                                         | +/−        |
|                  | PLA2G3                                       | +/−        |
|                  | INPP5A                                       | −/+        |
|                  | INPP5A                                       | −/+        |
|                  | HK2                                          | −/+        |
|                  | HK2                                          | −/+        |
|                  | DGKG                                         | +/−        |
|                  | PLA2G3                                       | +/−        |
|                  | INPP5A                                       | −/+        |
|                  | INPP5A                                       | −/+        |
|                  | DGKG                                         | +/−        |
|                  | PLA2G3                                       | +/−        |
|                  | INPP5A                                       | −/+        |
|                  | INPP5A                                       | −/+        |
|                  | DGKG                                         | +/−        |
|                  | PLA2G3                                       | +/−        |
|                  | INPP5A                                       | −/+        |
|                  | INPP5A                                       | −/+        |
|                  | DGKG                                         | +/−        |
|                  | PLA2G3                                       | +/−        |
|                  | INPP5A                                       | −/+        |
|                  | INPP5A                                       | −/+        |
|                  | DGKG                                         | +/−        |
|                  | PLA2G3                                       | +/−        |
|                  | INPP5A                                       | −/+        |
|                  | INPP5A                                       | −/+        |

*In the figure, we defined a two-component notation to classify the profiles of expression between mRNA target and miRNA, which indicates their relative expression. Red indicates the cases where mRNA overexpress and miRNA downregulate their expressions in Q-MCTS with respect to monoculture (+/−). Green indicates the inverse situation and it was denoted as −/+.*

### TABLE 3 | Pathways affected by the mRNA-miRNA pairs for the comparison between P-MCTS and monoculture.

| mRNA-miRNA Pairs | Pathway                                      | Expression |
|------------------|----------------------------------------------|------------|
| hsa-miR-429      | Glycerolipid metabolism                      | +/−        |
|                  | DGAT2                                        | +/−        |
|                  | GMPPB                                        | −/+        |
|                  | HK2                                          | −/+        |
|                  | HK2                                          | −/+        |
|                  | DGKG                                         | +/−        |
|                  | PLA2G3                                       | +/−        |
|                  | INPP5A                                       | −/+        |
|                  | INPP5A                                       | −/+        |
|                  | DGKG                                         | +/−        |
|                  | PLA2G3                                       | +/−        |
|                  | INPP5A                                       | −/+        |
|                  | INPP5A                                       | −/+        |
|                  | DGKG                                         | +/−        |
|                  | PLA2G3                                       | +/−        |
|                  | INPP5A                                       | −/+        |
|                  | INPP5A                                       | −/+        |
|                  | DGKG                                         | +/−        |
|                  | PLA2G3                                       | +/−        |
|                  | INPP5A                                       | −/+        |
|                  | INPP5A                                       | −/+        |
|                  | DGKG                                         | +/−        |
|                  | PLA2G3                                       | +/−        |
|                  | INPP5A                                       | −/+        |
|                  | INPP5A                                       | −/+        |
|                  | DGKG                                         | +/−        |
|                  | PLA2G3                                       | +/−        |
|                  | INPP5A                                       | −/+        |
|                  | INPP5A                                       | −/+        |
|                  | DGKG                                         | +/−        |
|                  | PLA2G3                                       | +/−        |
|                  | INPP5A                                       | −/+        |
|                  | INPP5A                                       | −/+        |
|                  | DGKG                                         | +/−        |
|                  | PLA2G3                                       | +/−        |
|                  | INPP5A                                       | −/+        |
|                  | INPP5A                                       | −/+        |
|                  | DGKG                                         | +/−        |
|                  | PLA2G3                                       | +/−        |
|                  | INPP5A                                       | −/+        |
|                  | INPP5A                                       | −/+        |
|                  | DGKG                                         | +/−        |
|                  | PLA2G3                                       | +/−        |
|                  | INPP5A                                       | −/+        |
|                  | INPP5A                                       | −/+        |

*To classify the profiles of expression between mRNA target and miRNA, we defined a two-component notation, which indicates their relative expression. Red shows the cases where mRNA overexpress and miRNA downregulate their expressions in P-MCTS with respect to monoculture (+/−). Green means the inverse situation, and it was denoted as −/+.*
FIGURE 4 | Pathway Enrichment Analysis. Statistical evaluation of the fraction of mRNAs in a particular pathway found in the DE mRNAs across comparisons and in the whole dataset. (A) Over-representation analysis. (B) GSEA. Comparison between Q-MCTS and P-MCTS. (C) GSEA. Comparison between Q-MCTS, and monoculture. (D) GSEA. Comparison between P-MCTS and monoculture. Orange, magenta, green and light blue bars show statistically enriched pathways for all data, Q-MCTS, P-MCTS, and monoculture, respectively.
mRNAs: KHK and GMPPB. The expression of these mRNAs shows an inverse phenotype: while KHK upregulates its expression, GMPPB downregulates its expression. This contrary behavior leads to an unclear pathway usage. In Q-MCTS, we found that KHK mRNA is mainly down-regulated by miR-3652, and GMPPB mRNA is down-regulated in monoculture by miR-1226-3p. This pathway could fuel the pentose phosphate flux and protein synthesis, indirectly increasing tumor growth (44). Also, there is experimental evidence indicating that fructose can be used by breast cancer cells specifically in glucose-deficiency environments (45) and the upregulation of KHK correlates with tumor malignancy and progression (46). Moreover, GMPPB overexpression is associated with a favorable prognostic value in endometrial cancer (47). Overall, we concluded that individual participation of these mRNAs may lead to a more severe phenotype for the monoculture model.

As discussed earlier, we observed a frequent disturbance in lipid metabolism through all comparisons. This metabolic preference remains in the comparison between Q-MCTS vs monoculture. Specifically, the glycerophospholipid metabolism is overexpressed...
in Q-MCTS. Based on our bioinformatics analysis, a possible explanation can be given due to the regulation on two miRNAs. We suggest that miR-501-5p down-regulates PLD3 and miR-7974 down-regulates DGKG and PLA2G3 in monoculture. Furthermore, CERS6 participating in the sphingolipid metabolism is overexpressed in monoculture, and is down-regulated by miR-3929 in Q-MCTS, see Figure 5B. Together these results showed that there is no particular usage for the lipid metabolism in general. However, the lipid categories can be exclusive to a cell cycle phase, for instance, the glycerophospholipid metabolism being constantly overexpressed in Q-MCTS.

Finally, the down-regulation of Glycosaminoglycan metabolism in Q-MCTS is accomplished through the regulation of miR-3652 over NDST1 and XYLT2. Conversely, in monoculture, these two mRNAs are overexpressed. Another result indicates that the inositol metabolism is up-regulated in monoculture, whereas in Q-MCTS this pathway is down-regulated by miR-663b, miR-3929, miR-3648, and miR-663a. Remarkably, both metabolic pathways are used to fuel signaling processes. In fact, glycosaminoglycans are part of the extracellular matrix (ECM), which conducted interactions with growth factors and cytokines implicated in cancer growth and progression, mainly signaling cascades responsible for regulating angiogenesis, invasion, and metastasis (48). Also, the mRNAs involved in the inositol metabolism can sustain the PI3K-dependent signaling pathways, promoting tumor growth and invasiveness (49). The up-regulation in monoculture for both metabolic pathways suggests that this preference is followed by the high proliferation rates observed, especially in this culture model.

**P-MCTS vs Monoculture Comparison**

The comparison between P-MCTS and monoculture reveals that P-MCTS primarily has low expression in miRNAs that control the biosynthesis of amino acids, inositol, valine, leucine, isoleucine, and lipid metabolism. For instance, we found that the monoculture solely down-regulates miR-492, which in turn regulates GFPT2, a mRNA participating in amino and nucleotide sugar metabolism (Table 3). The phenotype in this metabolic pathway is mainly influenced by two mRNAs: GFPT2 and GMPPB. The expression of these mRNAs shows an inverse phenotype. While one upregulates, the other downregulates its expression. In P-MCTS, GFPT2 mRNA is mainly down-regulated by miR-492, and GMPPB mRNA is down-regulated in monoculture by miR-940, miR4721, and miR-1226-3p. The abundance of the nucleotide pools limits the cancer proliferative capacity (50), suggesting that both models require this pathway to maintain their proliferative capacity, regardless of the pathway regulation.

Additionally, the comparative analysis showed an overexpression of mRNAs involved in the lipid metabolism in the P-MCTS. Mainly, the glycerolipid and glycerophospholipid metabolism are a consistent result across all comparisons, showing a preference in the MCTS models (Q-MCTS and P-MCTS). However, in monoculture this pathway is down-regulated by miR-429 targeting DGAT2, LPIN1, and miR-26a-5p targeting PCYT1A (Figure 5C). These results correlated with the fact that the highest levels in lipid profiles are found in the most aggressive breast tumors (51), suggesting that the lipid metabolism can promote malignancy in the MCTS models, despite the differences in the proliferation rates.

Likewise, our analysis showed an overexpression in the biosynthesis and degradation of amino acid in P-MCTS. Additionally, in monoculture, we suggested that the amino acid biosynthesis is down-regulated by miR-320c and miR-940 targeting PRPS1 and P Y C R 1 , respectively. Also, the amino acid degradation is down-regulated by miR-320c targeting HMGCSI, and ACADS B is down-regulated by a set of miRNAs; miR-19a-3p, miR454-3p, and miR-1226-3p (Figure 5C). These results agree with a proteome study in 3D cancer cultures (52), which suggest that spheroid cultures rely on amino acid utilization.

Finally, the overexpression in the inositol metabolism is accompanied by the up-regulation of PLCB4 and INPP5J in P-MCTS. Conversely, in monoculture, this pathway is down-regulated by miR-454-3p and miR-940, targeting these two mRNAs. These results suggest that this pathway and their corresponding fueled signaling pathways, such as PI3K, may be upregulated in the MCTS model.

**Altered Signaling Pathways**

Our analysis mainly focused on metabolic alterations; however, other pathways presented significant perturbations to explore more deeply. For instance, we found that pathways associated with cell division, DNA replication and repair are enriched in the proliferative-like models (P-MCTS and Monoculture). As we expected, these results are in agreement with the demands for sustaining a rapid proliferation. Complementary, inflammatory responses and immune suppression are enriched pathways for the Q-MCTS (Figure 4). Furthermore, our analysis makes evidence that Q-MCTS phenotype points to the overrepresentation in inflammatory cytokines, which have a key role in cancer progression via the stimulation of the epithelial-to-mesenchymal transition, and augmentation of metastasis in cancer (53). Another important and recurrent result is the overrepresentation of the ferroptosis. This pathway is characterized by iron-dependent accumulation of reactive oxygen species (ROS) within the cell, leading to cell death. Therefore, activation of ferroptosis derives in a selective elimination of some tumor cells (54). Together, these results suggest that the Q-MCTS can selectively enhance an invasive phenotype. As a whole, these observations mirror an orchestrated response to integrate the cancer phenotype, and it is in agreement with the fact that different tumor clonal subpopulations can diversify their task to maintain their growth and malignancy (14).

**Outlook**

Metabolic reprogramming plays an essential role in tumor development and metastasis. Besides, targeting cancer metabolism remains a great promise in developing anti-cancer therapies. As we propose here, several miRNAs may be controlling various metabolic pathways during MCTS progression. Although the model used in this study has limitations and the suggested interactions require subsequent experimental validation, we postulate the presence of new miRNAs-mRNA interactions that can modulate the metabolic landscape in the different cell populations that coexist during MCTS growth. In this context, other reports showed that miRNAs deregulation does not alter the
growth in normal cells, but it has a reduction in the growth of cancer cells (55–57). Although the progress in the effectiveness of miRNAs/anti-miRs delivery in vivo is still a major obstacle in clinics, our results highlight the miRNAs associated with metabolic changes in breast cancer as possible markers in peripheral blood since they are less labile than mRNAs and as therapeutic targets in cancer. Likewise, many functional activities of miRNAs and targets are unknown during tumor progression, so it is important to study them to understand how tumor cells propitiate its phenotype. Hopefully, our approaches and findings can be useful to verify experimentally these microRNA-mRNA interactions and explore their pragmatic implications for developing more effective cancer treatments that will target metabolic alteration within tumor subpopulations.

**DATA AVAILABILITY STATEMENT**

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: ArrayExpress, Accession: E-MTAB-9741 (https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-9741/).

**AUTHOR CONTRIBUTIONS**

EM-O and OR-A designed the project and developed the methods. EM-O performed the experiments and the bioinformatic analysis. EM-O and AV-J developed the functional analysis.

**REFERENCES**

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 116:281–97. doi: 10.1016/S0092-8674(04)00045-5
2. Tüfekci KU, Öner MG, Meuwissen RLJ, Genç S. The Role of MicroRNAs in Human Diseases. miRNomics: MicroRNA Biol Comput Anal (2011) 1107:33–50. doi: 10.1007/978-1-62703-748-8_3
3. Ling H, Fahbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discovery (2013) 12:847–65. doi: 10.1038/nrd4140
4. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell (2005) 120:15–20. doi: 10.1016/j.cell.2004.12.035
5. Hayes J, Peruzzi PP, Laval S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med (2014) 20:460–9. doi: 10.1016/j.molmed.2014.06.005
6. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature (2005) 435:834–8. doi: 10.1038/nature03702
7. Zabeer U, Faheem M, Qadri I, Begum N, Vassim HM, Al Thiari AA, et al. Expression profile of MicroRNA: An Emerging Hallmark of Cancer. Curr Pharm Des (2019) 25:642–53. doi: 10.2174/138620732266190325122821
8. Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol (2014) 9:287–314. doi: 10.1146/annurev-pathol-012513-104715
9. Chen B, Li H, Zeng X, Yang P, Liu X, Zhao X, et al. Roles of microRNA on cancer cell metabolism. J Transl Med (2012) 10:228. doi: 10.1186/1479-5876-10-228
10. Fang R, Xiao T, Fang Z, Sun Y, Li F, Gao Y, et al. MicroRNA-143 (miR-143) regulates cancer glycolysis via targeting hexokinase 2 gene. J Biol Chem (2012) 287:32237–35. doi: 10.1074/jbc.M111.373084
11. Ahmad A, Aboukameel A, Kong D, Wang Z, Raz A, Sarkar FH. Abstract 3361: Phosphoglucone isomerase/autoattirnity factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells. Tumor Biol (2011) 31:1245. doi: 10.1588/1538-7445.am.2011-3361
12. Jiang S, Zhang L-F, Zhang H-W, Hu S, Lu M-H, Liang S, et al. A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells. EMBO J (2012) 31:1985–98. doi: 10.1038/emboj.2012.45
13. Shah MA, Schwartz GK. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res (2001) 7:2168–81.
14. Muñoz-Olmos EA, Vázquez-Jiménez A, de León UA-P, Matadamas-Guzmán M, Maldonado V, López-Santalla T, et al. Unveiling functional heterogeneity in breast cancer multicellular tumor spheroids through single-cell RNA-sequencing. Sci Rep (2020) 10:1–16. doi: 10.1038/s41598-020-69026-7
15. Schafer KA. The cell cycle: a review. Vet Pathol (1998) 35:461–78. doi: 10.1177/030098589803500601
16. Schwartz GK, Shah MA. Targeting the Cell Cycle: A New Approach to Cancer Therapy. J Clin Oncol (2005) 23:9408–21. doi: 10.1200/jco.2005.01.5594
17. Witswald L-B, Bellet D, Danglies-Marie V. Spherical cancer models in tumor biology. Neoplasia (2015) 17:1–15. doi: 10.1016/j.neo.2014.12.004
18. Laurent J, Frongia C, Cazales M, Mondesert O, Ducommun B, Lobijos V. Multicellular tumor spheroid models to explore cell cycle checkpoints in 3D. BMC Cancer (2013) 13:73. doi: 10.1186/1471-2407-13-73
19. Desoize B, Jardillier J. Multicellular resistance: a paradigm for clinical resistance? Crit Rev Oncol Hematol (2000) 36:193–207. doi: 10.1016/S1040-8428(00)00086-X
20. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin (2018) 68:394–424. doi: 10.3322/caac.21492

**FUNDING**

The authors thank the financial support from an internal grant of the National Institute of Genomic Medicine.

**ACKNOWLEDGMENTS**

OR-A thanks to the financial support coming from INMEGEN México. EM-O is a doctoral student from Programa de Doctorado en Ciencias Biomédicas, Universidad Nacional Autónoma de México (UNAM) and has received CONACyT fellowship 735969. Thanks to the training and support in the MCTS culture procedures to Dr. Edna Ayerim Mandujano-Tinoco and Dr. Alfredo García-Venzor, to Linda Nelly Patiño Uriostegui for FACs analysis, to José Luis Cruz Colin for his support in cell culture and Alfredo Mendoza-Vargas for his support in the sequencing protocols (Instituto Nacional de Medicina Genómica).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2020.582396/full#supplementary-material
21. Mandujano-Tinoco EA, García-Venzo A, Muñoz-Galindo L, Lizarraga-Sanchez F, Favela-Orozco A, Chávez-Gutiérrez E, et al. miRNA expression profile in multicellular breast cancer spheroids. Biochim. Biophys. Acta Mol Cell Res (2017) 1864:1642–55. doi: 10.1016/j.bbamcc.2017.05.023

22. Legland D, Arganda-Carreras I, Andre P. MorphoLibJ: integrated library and plugins for mathematic morphology with ImageJ. Bioinformatics (2016) 32:3532–4. doi: 10.1093/bioinformatics/btw413

23. Ewels P, Magnusson M, Lundin S, Käller M. MultiQC: summarize analysis results for multiple tools and samples in a single report. Bioinformatics (2016) 32:3047–8. doi: 10.1093/bioinformatics/btw354

24. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics (2014) 30:2114–20. doi:10.1093/bioinformatics/btu170

25. Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol (2016) 34:523–7. doi: 10.1038/nbt.3519

26. Soneson C, Love MI, Robinson MD. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Res (2015) 4:1521. doi: 10.12688/f1000research.7563.1

27. Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol (2016) 34:523–7. doi: 10.1038/nbt.3519

28. Ziemann M, Kaspi A, El-Osta A. Evaluation of microRNA alignment plugins for mathematical morphology with ImageJ. Bioinformatics (2016) 32:3532–4. doi: 10.1093/bioinformatics/btw413

29. Liao Y, Smyth GK, Shi W. featureCounts: an ef

30. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics (2014) 30:2114–20. doi:10.1093/bioinformatics/btu170

31. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods (2012) 9:154–60. doi: 10.1038/nmeth.f.303

32. Ziemann M, Kaspi A, El-Osta A. Evaluation of microRNA alignment plugins for mathematical morphology with ImageJ. Bioinformatics (2016) 32:3532–4. doi: 10.1093/bioinformatics/btw413

33. Andre

34. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics (2014) 30:2114–20. doi:10.1093/bioinformatics/btu170

35. McCarthy DJ, Chen Y, Smyth GK. Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. Nucleic Acids Res (2012) 40:4288–97. doi: 10.1093/nar/gks042

36. Soneson C, Love MI, Robinson MD. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Res (2015) 4:1521. doi: 10.12688/f1000research.7563.1

37. Tili E, Michaille J-J, Luo Z, Volinia S, Rassenti LZ, Kipps TJ, et al. The down

38. Martinez-Zaguilan R, Lynch RM, Martinez GM, Gillies RJ. Vacuolar-type H

39. Martinez-Zaguilan R, Lynch RM, Martinez GM, Gillies RJ. Vacuolar-type H

40. Feng S, Zhu G, McConnell M, Deng L, Zhao Q, Wu M, et al. Silencing of atp6v1c1 prevents breast cancer growth and bone metastasis. Int J Biol Sci (2013) 9:853–62. doi: 10.7150/ijbs.6030

41. Lau KS, Dennis JW. N-Glycans in cancer progression. Glyobiology (2008) 18:750–60. doi: 10.1093/glycob/cwn071

42. Hsu J-M, Xia W, Hsu Y-H, Chan L-C, Yu W-H, Cha J-H, et al. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nat Commun (2018) 9:1908. doi:10.1038/s41467-018-04133-6

43. Yen J, Ren W, Huang X, Deng J, Li T, Yin Y. Potential Mechanisms Connecting Purine Metabolism and Cancer Therapy. Front Immunol (2018) 9:1697. doi: 10.3389/fimmu.2018.01697

44. Port AM, Ruth MR, Istan NW. Fructose consumption and cancer. Curr Opin Endocrinol Diabetes Obes (2012) 19:367–74. doi:10.1097/mdo.0b013e3283578fcb

45. Fan X, Liu H, Liu M, Wang Y, Qiu L, Cui Y. Increased utilization of fructose has a positive effect on the development of breast cancer. PeerJ (2017) 5:e3804. doi: 10.7717/peerj.3804

46. Gao W, Li N, Li Z, Xu J, Su C. Ketoheoxokinase is involved in fructose utilization and promotes tumor progression in glioma. Biochem Biophys Res Commun (2018) 503:1298–306. doi: 10.1016/j.bbrc.2018.07.040

47. Wang Z-H, Zhang Y-Z, Wang Y-S, Ma X-X. Identification of novel cell glycolysis related gene signature predicting survival in patients with endometrial cancer. Cancer Cell Int (2019) 19:1–13. doi:10.1186/s12935-019-1001-0

48. Afratis N, Gialeli C, Nikitovic D, Tsegenidis T, Karousou E, Theocharis AD, et al. Glycosaminoglycans: key players in cancer cell biology and treatment. FEBS J (2012) 279:1177–97. doi: 10.1111/j.1742-4658.2012.08592.x

49. Tan J, Yu C-Y, Wang Z-H, Chen H-Y, Guan J, Chen Y-X, et al. Genetic variants in the inositol phosphate metabolism pathway and risk of different types of cancer. Sci Rep (2015) 5:8473. doi: 10.1038/srep08473

50. Tong X, Zhao F, Thompson CB. The molecular determinants of de novo nucleotide biosynthesis in cancer cells. Curr Opin Genet Dev (2009) 19:32–7. doi: 10.1016/j.gde.2009.01.002

51. Hilvo M, Denkert C, Lehtinen L, Müller B, Brockmöller S, Seppänen-Laakos T, et al. Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. Cancer Res (2011) 71:3236–45. doi: 10.1158/0008-5472.CAN-10-3894

52. Yue X, Lukowski JK, Weaver EM, Skube SB, Hummon AB. Quantitative Proteomic and Phosphoproteomic Comparison of 2D and 3D Colon Cancer Cell Culture Models. J Proteome Res (2015) 14:4265–76. doi: 10.1021/acs.jproteome.6b00342

53. Diakos CI, Charles KA, McMillan DC, Clarke SJ, Cancer-related inflammation and treatment effectiveness. Lancet Oncol (2014) 15:e493–503. doi: 10.1016/ s1470-2045(14)70263-3

54. Afratis N, Gialeli C, Nikitovic D, Tsegenidis T, Karousou E, Theocharis AD, et al. Glycosaminoglycans: key players in cancer cell biology and treatment. FEBS J (2012) 279:1177–97. doi: 10.1111/j.1742-4658.2012.08592.x

55. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Karousou E, Theocharis AD, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell (2012) 149:1060–72. doi: 10.1016/j.cell.2012.03.042

56. Hatzipostolou M, Polytarchou C, Iliopoulos D. miRNAs link metabolic reprogramming to oncogenesis. Trends Endocrinol Metab (2013) 24:561–73. doi: 10.1016/j.tem.2013.03.002

57. Drakaki A, Hatzipostolou M, Iliopoulos D. Therapeutically Targeting MicroRNAs in Liver Cancer. Curr Pharm Des (2012) 18:1190–81. doi: 10.2174/138161213804080568

58. Chan B, Manley J, Lee J, Singh SR. The emerging roles of microRNAs in cancer metabolism. Cancer Lett (2015) 356:301–8. doi: 10.1016/j.canlet.2014.10.011

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Muñoz-Olmos, Vázquez-Jimenez, López-Espera, Maldonado, Valverde and Resendiz-Antonio. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.